Literature DB >> 7876617

Elevated levels of activities of beta-hexosaminidase and alpha-mannosidase in human immunodeficiency virus-infected patients.

N Lügering1, R Stoll, A Siekmann, J Faulhaber, C Heese, O Dietrich, T Kucharzik, H Busch, A Hasilik, W Domschke.   

Abstract

To determine their value as markers of the clinical stage of human immunodeficiency virus (HIV) disease, plasma activities of lysosomal glycosidases were determined in the plasma of 97 HIV-infected patients: molecular forms of cathepsin D were characterized by Western blot to examine the mode of enzyme release. In patients with Centers for Disease Control and Prevention stage II and III of HIV disease, plasma activity of beta-hexosaminidase was significantly increased. In patients with stage III infection, alpha-mannosidase activity was also significantly increased and cathepsin D was elevated and present only in its premature form. Thus, determination of plasma activities of beta-hexosaminidase and alpha-mannosidase in HIV-positive persons may be useful for distinguishing the clinical stage of disease. The elevation of precursors of cathepsin D in patients with stage III HIV disease indicates that secretion of lysosomal enzymes rather than leakage of enzymes from damaged cells is markedly elevated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7876617     DOI: 10.1093/infdis/171.3.683

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  IL-10 synergizes with IL-4 and IL-13 in inhibiting lysosomal enzyme secretion by human monocytes and lamina propria mononuclear cells from patients with inflammatory bowel disease.

Authors:  N Lügering; T Kucharzik; H Stein; G Winde; A Lügering; A Hasilik; W Domschke; R Stoll
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

2.  Serum 27E10 antigen: a new potential marker for staging HIV disease.

Authors:  N Lügering; R Stoll; T Kucharzik; G Burmeister; C Sorg; W Domschke
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.